AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9745414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (including high dose i.v. methotrexate)
Number of subjects: 22
Study 9745414 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose i.v. methotrexate
Number of subjects: 22
Study 9745414 — intervention group
Group type: COMPARATOR
Intervention: Control group (children who did not receive high dose i.v. methotrexate)
Number of subjects: 22
Study 7997610 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopentol 350 mgI/ml
Number of subjects: 100
Study 7997610 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol 370 mgI/ml
Number of subjects: 100
Study 3377206 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg lorazepam intravenously
Number of subjects: 15
Study 3377206 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg/kg secobarbital
Number of subjects: 15
Study 3377206 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 15
Study 4853118 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a checklist for side effect collection
Number of subjects: 0
Study 4853118 — intervention group
Group type: COMPARATOR
Intervention: No checklist for side effect collection
Number of subjects: 0
Study 30864279 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil-based parenteral lipid emulsion (PLE), n = 35
Number of subjects: 66
Study 30864279 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3-enriched parenteral lipid emulsion (PLE), n = 31
Number of subjects: 66
Study 30864279 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 66
Study 29666120 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL Vivinex XY1
Number of subjects: 66
Study 29145410 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive flexibility training
Number of subjects: 97
Study 29145410 — intervention group
Group type: COMPARATOR
Intervention: Mock training (active control)
Number of subjects: 97
Study 29145410 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 97
Study 25569185 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART regimen (budesonide/formoterol)
Number of subjects: 303
Study 25569185 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (salbutamol)
Number of subjects: 303
Study 25569185 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 303
Study 25569185 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 303
Study 23620938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needle combined with narrow band ultraviolet-B (NB-UVB) therapy
Number of subjects: 93
Study 23620938 — intervention group
Group type: COMPARATOR
Intervention: Narrow band ultraviolet-B (NB-UVB) therapy
Number of subjects: 93
Study 21148423 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TSP-1
Number of subjects: 184
Study 21148423 — intervention group
Group type: EXPERIMENTAL
Intervention: TSP-1(−/−) mice
Number of subjects: 184
Study 21148423 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections of TSP-1 in C57Bl6/J mice after hindlimb ischemia
Number of subjects: 184
Study 18991190 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNFalpha treatment (adalimumab and infliximab) for 18 months
Number of subjects: 12
Study 18991190 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNFalpha treatment
Number of subjects: 12
Study 17663340 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment and filling (Group A)
Number of subjects: 60
Study 17663340 — intervention group
Group type: COMPARATOR
Intervention: Porcelain complete veneer crown (Group B)
Number of subjects: 60
Study 15178468 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-stress condition (n=21)
Number of subjects: 40
Study 15178468 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stress condition
Number of subjects: 40
Study 15178468 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked presentations of snake words
Number of subjects: 40
Study 15178468 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked Stroop interference
Number of subjects: 40
Study 15178468 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched controls (n=21)
Number of subjects: 40
Study 11572248 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck dissection followed by chemoradiotherapy (Group I)
Number of subjects: 54
Study 11572248 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy alone (Group II)
Number of subjects: 54
Study 9692392 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin plus ciprofloxacin (PC)
Number of subjects: 96
Study 9692392 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin plus gentamicin (PG)
Number of subjects: 96
Study 7939369 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (3.4 g eicosapentaenoic and docosahexaenoic acid per day)
Number of subjects: 57
Study 7939369 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 7939369 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Number of subjects: 57
Study 7939369 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids and Control group combined
Number of subjects: 57
Study 7939369 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids and Control group
Number of subjects: 57
Study 3330601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg
Number of subjects: 69
Study 3330601 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg
Number of subjects: 69
Study 31813076 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing internalized stigma
Number of subjects: 200
Study 31813076 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing anticipated stigma
Number of subjects: 200
Study 31813076 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing intimate partner violence (IPV)
Number of subjects: 200
Study 31813076 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing IPV
Number of subjects: 200
Study 31813076 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing depression
Number of subjects: 200
Study 29611500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic water filters (CWFs)
Number of subjects: 240
Study 28882920 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT TRICK programme (12-week face-to-face intervention)
Number of subjects: 60
Study 26187227 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared medical appointments (SMAs)
Number of subjects: 272
Study 26187227 — intervention group
Group type: COMPARATOR
Intervention: Individual annual appointments
Number of subjects: 272
Study 24139135 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter venography (CV) + Intravascular ultrasound (IVUS)
Number of subjects: 20
Study 24139135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 20
Study 24139135 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance venography (MRV)
Number of subjects: 20
Study 24139135 — intervention group
Group type: COMPARATOR
Intervention: Doppler sonography (DS)
Number of subjects: 20
Study 24139135 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive screening methods
Number of subjects: 20
Study 21178598 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group (240 mg lidocaine in 125 mL saline once a week for 4 weeks)
Number of subjects: 30
Study 21178598 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy group (25 mg amitriptyline with 125 mL saline)
Number of subjects: 30
Study 18315472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily)
Number of subjects: 95
Study 18315472 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (2 mg daily)
Number of subjects: 95
Study 18315472 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 95
Study 17237993 — intervention group
Group type: EXPERIMENTAL
Intervention: New health sector reform program
Number of subjects: 0
Study 17237993 — intervention group
Group type: COMPARATOR
Intervention: Other types of units
Number of subjects: 0
Study 12556735 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (a selective dopamine-1 receptor agonist)
Number of subjects: 0
Study 12556735 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10878675 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (40 mg)
Number of subjects: 12
Study 10878675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8932264 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppression (female donors)
Number of subjects: 397
Study 8932264 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppression (pediatric en bloc kidneys)
Number of subjects: 397
Study 8932264 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppression (donors over 60 years of age)
Number of subjects: 397
Study 1546122 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 68
Study 1546122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 3920390 — intervention group
Group type: EXPERIMENTAL
Intervention: Superstuff
Number of subjects: 43
Study 3920390 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 31904578 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-fully automated emails (S)
Number of subjects: 458
Study 31904578 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard plus personalized SMS (S+pSMS)
Number of subjects: 458
Study 31904578 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard plus weekly videoconferencing support (S+VCS)
Number of subjects: 458
Study 30087557 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative expression therapy (CrExp)
Number of subjects: 93
Study 30087557 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive training (Control)
Number of subjects: 93
Study 27776442 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month aerobic exercise intervention
Number of subjects: 161
Study 27776442 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161
Study 25012003 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 5mg daily for three months prior to surgery
Number of subjects: 47
Study 25012003 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment daily for three months prior to surgery
Number of subjects: 47
Study 25012003 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 5mg
Number of subjects: 47
Study 25012003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 25012003 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor treatment
Number of subjects: 47
Study 22100423 — intervention group
Group type: EXPERIMENTAL
Intervention: V.A.C.™ system (group A)
Number of subjects: 42
Study 22100423 — intervention group
Group type: COMPARATOR
Intervention: RENASYS GO™ - F/P (group B)
Number of subjects: 42
Study 20309785 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching groups (6 groups with different techniques and durations)
Number of subjects: 173
Study 20309785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 173
Study 18778329 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based HIV prevention intervention
Number of subjects: 6791
Study 18778329 — intervention group
Group type: COMPARATOR
Intervention: Deferred intervention implementation (Control)
Number of subjects: 6791
Study 15917842 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ghrelin infusion (1 pmol/kg/min)
Number of subjects: 24
Study 15917842 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ghrelin infusion (5 pmol/kg/min)
Number of subjects: 24
Study 15917842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion
Number of subjects: 24
Study 12069875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent injections of a staphylococcus toxoid
Number of subjects: 100
Study 12069875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10353862 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg/day
Number of subjects: 24
Study 10353862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8955542 — intervention group
Group type: EXPERIMENTAL
Intervention: NART-R
Number of subjects: 47
Study 8955542 — intervention group
Group type: EXPERIMENTAL
Intervention: NART
Number of subjects: 47
Study 1770183 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate (0.3 mg/kg)
Number of subjects: 21
Study 1770183 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 7048770 — intervention group
Group type: EXPERIMENTAL
Intervention: combined diet training programme
Number of subjects: 23
Study 7048770 — intervention group
Group type: COMPARATOR
Intervention: unique dietary treatment
Number of subjects: 23
Study 31574151 — intervention group
Group type: COMPARATOR
Intervention: No intervention (untreated)
Number of subjects: 43
Study 28952824 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/beta-TCP combination
Number of subjects: 6
Study 28952824 — intervention group
Group type: COMPARATOR
Intervention: beta-TCP
Number of subjects: 6
Study 26787567 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC 1200 mg orally before angiography and 1200 mg orally twice daily for three doses along with good hydration
Number of subjects: 105
Study 26787567 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC 600 mg before angiography and 600 mg orally twice daily for three doses plus ascorbic acid (3000 mg one dose) before angiography and 2000 mg two doses after angiography and good hydration
Number of subjects: 105
Study 26787567 — intervention group
Group type: COMPARATOR
Intervention: Hydration with 0.9% saline started just before contrast media injection and continued for 12 h at a rate 1.0 mL/kg/min after angiography or 0.5 mL/kg/h in cases with overt heart failure for 12 h
Number of subjects: 105
Study 25194928 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality training (EG)
Number of subjects: 60
Study 25194928 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy or occupational therapy (Control)
Number of subjects: 60
Study 22245458 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube shunt (350‐mm² Baerveldt glaucoma implant)
Number of subjects: 212
Study 22245458 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (0.4 mg/mL for 4 minutes)
Number of subjects: 212
Study 19584820 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated G-CSF
Number of subjects: 86
Study 19584820 — intervention group
Group type: COMPARATOR
Intervention: Non-glycosylated G-CSF
Number of subjects: 86
Study 17706004 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin (7.5 mg once daily for 2 weeks, then optional titration to 15 mg daily)
Number of subjects: 400
Study 17706004 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with sham titration)
Number of subjects: 400
Study 16080839 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol
Number of subjects: 92
Study 16080839 — intervention group
Group type: COMPARATOR
Intervention: captopril
Number of subjects: 92
Study 12034650 — intervention group
Group type: EXPERIMENTAL
Intervention: (192)Ir radiation
Number of subjects: 70
Study 12034650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9929503 — intervention group
Group type: EXPERIMENTAL
Intervention: tizanidine HCl, 4 mg t.i.d. for seven consecutive doses
Number of subjects: 15
Study 9929503 — intervention group
Group type: EXPERIMENTAL
Intervention: baclofen, 10 mg t.i.d. for seven consecutive doses
Number of subjects: 15
Study 9929503 — intervention group
Group type: EXPERIMENTAL
Intervention: both regimens simultaneously for seven consecutive doses
Number of subjects: 15
Study 8552457 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional model of a house with raised-line drawing kit
Number of subjects: 30
Study 8552457 — intervention group
Group type: COMPARATOR
Intervention: Prior information about the nature of the tangible pictures (side view, bird's-eye, top view, or 3/4 view)
Number of subjects: 30
Study 2359305 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective diary measure
Number of subjects: 156
Study 2359305 — intervention group
Group type: COMPARATOR
Intervention: 28‐day Q‐F measure
Number of subjects: 156
Study 2359305 — intervention group
Group type: COMPARATOR
Intervention: Standard instructions with confidentiality verification
Number of subjects: 156
Study 2359305 — intervention group
Group type: COMPARATOR
Intervention: 7‐day Q‐F measure
Number of subjects: 156
Study 11144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 50 mg
Number of subjects: 8
Study 11144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 100 mg
Number of subjects: 8
Study 11144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 8
Study 11144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 8
Study 11144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29945431 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 0 ng/mL
Number of subjects: 60
Study 29945431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.25 ng/mL
Number of subjects: 60
Study 29945431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.5 ng/mL
Number of subjects: 60
Study 28655357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention as part of a hospital ward team
Number of subjects: 212
Study 26228205 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training with Cognitive Load (VRTCL) for 4 weeks (30 min per day, five times a week)
Number of subjects: 22
Study 26228205 — intervention group
Group type: COMPARATOR
Intervention: Control group (virtual reality treadmill training)
Number of subjects: 22
Study 26228205 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training with Cognitive Load (VRTCL)
Number of subjects: 22
Study 23542157 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at 2 Hz, 0.4 ms to right LI4 and LI11 for 30 min
Number of subjects: 36
Study 23542157 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation to bilateral patellae
Number of subjects: 36
Study 23542157 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture to right LI4 and LI11 over Duoderm pads
Number of subjects: 36
Study 21724699 — intervention group
Group type: EXPERIMENTAL
Intervention: UCLA SCTC GIT 2.0
Number of subjects: 115
Study 19258524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 12.5 mg/kg and Pseudoephedrine (PSE) HCl 15 or 30 mg
Number of subjects: 318
Study 19258524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 12.5 mg/kg
Number of subjects: 318
Study 19258524 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (PSE) HCl 15 or 30 mg
Number of subjects: 318
Study 19258524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 16957639 — intervention group
Group type: EXPERIMENTAL
Intervention: RIC device (silver-coated endotracheal tube)
Number of subjects: 149
Study 16957639 — intervention group
Group type: COMPARATOR
Intervention: Control endotracheal tube
Number of subjects: 149
Study 15316843 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary DDD pacing at 90 bpm
Number of subjects: 6
Study 15316843 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary DDD pacing at 110 bpm
Number of subjects: 6
Study 15316843 — intervention group
Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 6
Study 11941377 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 500
Study 11941377 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 600-650 mg
Number of subjects: 500
Study 9780137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.75% THC
Number of subjects: 6
Study 9780137 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.55% THC
Number of subjects: 6
Study 9780137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7540794 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (7.5 to 10 mg a day)
Number of subjects: 0
Study 7540794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2587847 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich omega-3 fatty acids at 3g/d
Number of subjects: 0
Study 2587847 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich omega-3 fatty acids at 6g/d
Number of subjects: 0
Study 2587847 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich omega-3 fatty acids at 12g/d
Number of subjects: 0
Study 2587847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11564 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists (metiamide and cimetidine)
Number of subjects: 46
Study 11564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31830933 — intervention group
Group type: EXPERIMENTAL
Intervention: New Hope
Number of subjects: 304
Study 31830933 — intervention group
Group type: EXPERIMENTAL
Intervention: Elders' Resilience
Number of subjects: 304
Study 31830933 — intervention group
Group type: EXPERIMENTAL
Intervention: New Hope followed by Elders' Resilience
Number of subjects: 304
Study 31830933 — intervention group
Group type: COMPARATOR
Intervention: Optimized Case Management
Number of subjects: 304
Study 28134543 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative statements (ES)
Number of subjects: 6492
Study 28134543 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated evaluative pairings (REP)
Number of subjects: 6492
Study 28134543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of evaluative statements and repeated evaluative pairings (ES + REP)
Number of subjects: 6492
Study 28134543 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit Association Test (IAT)
Number of subjects: 6492
Study 26248813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (5mg daily)
Number of subjects: 24